Healthtech Partnering Week Preliminary Speaker Lineup

11 Feb

By Rory McCann, Marketing Manager & Conference Producer, LSN

Healthtech Partnering Week, March 15-19, is right around the corner! The 5-day digital partnering event consists of three conferences focusing on different areas within life science and healthcare. Redefining Early Stage Investments (RESI) broadly covers investor insights for fundraising executives within healthtech, biotech, and medtech. 4D Meets AI specifically tackles the investor-founder relationship, from pitch to partner, while working with AI technology in drugs, devices, diagnostics, and digital health (4Ds). Longevity, Health & Innovation, co-organized with Mary Furlong & Associates, provides a big-picture approach to the investment ecosystem, as well as market overview and regulatory landscape for early-stage age-tech and innovation enabling seniors to live longer, better lives.

Life Science Nation (LSN) is pleased to introduce our preliminary speaker lineup, featuring investors and industry experts sharing their experiences and offering insights to help fundraising companies succeed in the early stages.

Interested in joining a panel? Visit www.healthtechpartneringweek.com to learn more about each conference. Fundraising in 2021, and looking to meet with active investors? Join us and save on our early-bird rates by February 19!

Featured Healthtech Partnering Week Panelists


Sascha Berger
Partner
TVM Capital Life Science

Diagnostics
Jean Anne Booth
CEO
UnaliWear Inc.

Devices
Nat Brinn
Partner
VC23

Tools and R&D Services
Barbara Clarke
Founder & President
The Impact Seat

Investing in New, Now, and Next

Evan Cohen
Associate Principal, Strategic Investing
Healthbox

Digital Health for the Elderly
Michele Colucci
Managing Partner
DigitalDx Ventures

Diagnostics
Terence Craig
Chief Investment Officer
The Impact Seat

Devices
Bettina Ernst
Director
BERNINA BioInvest

Investing in New, Now, and Next

Howard Fillit
Founding Executive Director and CSO
Alzheimers Drug Discovery Foundation

Early Detection of CNS Disorders
Robert Garber
Partner
7wire Ventures

Investing in New, Now, and Next
Amit Garg
Managing Partner
Tau Ventures

Digital Health
Scott Gazelle
Managing Partner
GreyBird Ventures

Diagnostics

Tom Gibbs
Director
Debiopharm Innovation Fund

Digital Health
Katherine Hill Ritchie
Director
Nottingham Spirk Family Office

Medical Devices
Alicia Irurzun-Lafitte
Partner
UCB Ventures

Cell & Gene Therapy
Justin Kelly
Associate
AXA Venture Partners

Digital Health for the Elderly

Oliver Keown
Director, Intuitive Ventures
Intuitive Surgical

Combination Devices
Lily Kim
Scientific Director
OS Fund

Tools and R&D Services
Kristin King
Member
Boston Harbor Angels

Medical Devices
Richard Kivel
Managing Director
GrayBella Capital

Diagnostics

Daniella Kranjac
Founding Partner
Dynamk Capital

Tools and R&D Services
Taja Lester
Managing Partner
Health Equity Capital

Digital Health for the Elderly
George Li
Managing Partner
Proxima Ventures

Diagnostics
Jonathan Ng
CEO
Iterative Scopes

Digital Health

Jeffrey Ries
Managing Director
Healthbox

Digital Health
Kerry Rupp
General Partner
True Wealth Ventures

Digital Health for the Elderly
Chirag Shah
Principal
Define Ventures

Digital Health
Patrik Sobocki
Investment Manager Life Science
Industrifonden

Digital Health

Catello Somma
Associate
TVM Capital Life Science

Early Stage Therapeutics
Weiyong Sun
Senior Director, Specialty Medicine Search & Evaluation
Daiichi Sankyo

Cell & Gene Therapy
Tad Weems
Managing Director
Agilent Technologies

Tools and R&D Services

Best Practices in Conference Partnering: Join Our Free Webinar

11 Feb

 

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Life Science Nation (LSN)’s mission is to connect early-stage companies in life science and healthcare with investment capital that is a fit based on product and stage of development. LSN’s partnering system is unique in that it contains search functionality to help fundraising executives narrow down to the best investors for their needs, removing the question, “Is this a good fit?”

While LSN cannot make the deal for you, we can help you connect with the contacts you need to succeed in your raise and growth. We can also prepare you with tried-and-true tips to make your partnering experience exceptional, letting your technology, product, and team take center-stage as you pitch to investors.

Sign up for our free webinar, Strategies for Successful Partnering, taking place February 17, 12 PM EST. Whether Seed or Series B, our methods have assisted early-stage companies in raising millions of dollars, and we hope to add yours to our growing list of success stories!

Are you fundraising and looking to meet with investors who fit your product set and stage of development? Sign up for Healthtech Partnering Week, March 15-19, by February 19 to save on early-bird rates!

Workshops at Healthtech Partnering Week

11 Feb

By Gregory Mannix, Vice President International Business Development, LSN

Workshops at Healthtech Partnering Week are live webinars designed to educate leaders of fundraising companies on elements of the early-stage landscape often overlooked, which can include patents, recruitment, intellectual property, insurance, financial management, and so much more. Check out some of the great content coming your way this March:

Venture Valuation provides global valuation services by assessing companies and products. Founded in 1999 by Dr. Patrik Frei, Venture Valuation has done over 700 valuations for biotech, pharma, and medtech companies around the world, and supports companies’ growth with entrepreneurial education and industry insight.

The Venture Valuation team is bringing their expertise to Healthtech Partnering Week, March 15-19 with two workshops: Company Valuation for Fundraising and Product Valuation for Deal-Making. Each workshop is designed to provide early-stage founders with practical insight into financing and licensing trends, valuation approaches, licensing negotiations, and finding the right investors and strategic partners.

These skills are a necessary component to the growth of early-stage companies, and we invite all start-ups in life science and healthcare to get to know the Venture Valuation team and take advantage of their expertise by joining us at Healthtech Partnering Week.

Sign up to save on early-bird rates by February 19!

Patrik Frei, PhD
CEO
Venture Valuation

Gergely Ivanyi, PharmD
Business Analyst
Venture Valuation

Elias Neuendorf, MSc
Business Analyst
Venture Valuation

Company Valuation for Fundraising

Instructors: Patrik Frei, PhD, CEO, Venture Valuation
Gergely Ivanyi, PharmD, Business Analyst, Venture Valuation
Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, it’s important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don’ts when speaking with investors and look at how to value a life science company with no revenues.

Topics include, but are not limited to:

    • Overview financing trends
  • Which is the right investor?
  • Dos and don’ts
  • Company valuation approaches

Product Valuation for Deal-Making

Instructors: Patrik Frei, PhD, CEO, Venture Valuation
Elias Neuendorf, MSc, Business Analyst, Venture Valuation
Companies looking at in- or out-licensing need to understand the value dynamics of their product to negotiate realistic deal-terms. Successful business development depends on understanding the fundamentals as well as keeping up with the latest licensing deal trends. We will be looking at the latest deals including up-front and total deal values for different stages and indications and discuss the fundamental valuation approach to asset/product valuation as a basis to estimate possible licensing deal terms.

Topics include, but are not limited to:

  • Overview licensing deal and trends
  • How to find the right licensing partner
  • Asset/Product valuation approach
  • Licensing deal negotiation

If you’re interested in hosting a workshop or panel at Healthtech Partnering Week, our Business Development Team is happy to learn more in order to meet your goals. Contact us to start the conversation!

Hot Investor Mandate: VC Firm Invests Up to $10M in USA & European Diagnostics & Digital Health Technologies that Seek China Market Expansion

11 Feb

A venture capital firm founded in 2002 is looking to invest in tech-based digital health and diagnostics companies looking to expand to the Chinese market. The firm primarily invests in European companies, but will consider companies based in the US as well. The firm looks to leverage their connections to China and the Chinese market on behalf of its portfolio companies. The firm looks to invest between $2-10M in companies, taking a 15-30% equity stake. The firm prefers to be a lead investor, taking an active role in their portfolio companies, and will invest in about 2 companies a year, depending on their fund cycle. In cases where The firm does not invest funds, they are also willing to offer consulting services for equity, connecting companies with strategic partners in China.

The firm has an additional partnership model that, instead of direct investment, licenses technologies through a Chinese platform company, acting as a focused distributor for entry into the Chinese market. This is the firm’s alternate investment approach to bringing these technologies to the Chinese market, by utilizing this Chinese platform company to serve as their portfolio company’s representative in China to navigate the regulatory environment and spearhead all of the sales and marketing.

The firm is interested in tech companies that are not consumer focused. The firm looks for companies such as diagnostics tools or AI/machine learning technologies in the healthcare space. The firm has some experience with pathology diagnostic related companies, but is willing to consider other areas as well. The firm prefers to invest in a few companies within the same area, choosing complementary technologies between their portfolio companies. The firm will consider companies with technologies that are in development or in pilot stages.

The firm is an active investor and takes a board seat for every company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Capital Arm of Europe Bank Invests in Therapeutics, Devices, Diagnostics, Digital Health from Late Seed to Series B

11 Feb

A venture capital arm of an Europe-headquartered bank invests in early-stage companies in the life science industry among other technologically oriented industries, and is looking to engage in late seed, Series A or Series B rounds. The initial investments typically range from 0.5M to 3M Euros. The firm is open to both leading and co-investing, and prefer to syndicate with other investors. The firm is primarily interested in companies based in Germany, Austria and Switzerland.

The firm is looking for new opportunities in the life science space including therapeutics, diagnostics, medical devices and digital health. The firm is interested in companies from pre-clinical to clinical stages onward, and would like to see some preclinical validations for therapeutics companies or prototypes for medical devices. The firm is opportunistic in terms of sector, subsectors and indications, and is open to considering orphan diseases.

The firm doesn’t have specific requirements for management teams. The firm is open to both leading and co-investing, and prefers to take a board seat when investing larger amounts.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Healthcare VC Invests Broadly Across All Life Science Companies with Strong Market Opportunities in USA, Europe, China

11 Feb

A venture capital firm with offices in USA and China invests exclusively in healthcare companies (therapeutics, medical devices, digital health, and healthcare services). The firm typically invests $1-5M (USD) of equity capital with the ability to make follow-on investment. The fund aims to make at least 5 investments per year, but this is not a fixed number. In general, the firm participates in seed, series A and series B funding rounds. The firm looks at companies of all parts of the world and has a strong preference for companies that have market opportunities in the US, Europe and China. The firm’s China office can provide companies with the resources they need for successful market entry in Asian markets.

The firm looks at all sectors pertaining to healthcare, including biotech therapeutics, R&D services, diagnostics, medical devices, and digital health. While the firm’s focus is in early-stage companies, it takes a very opportunistic viewpoint. In therapeutics, the firm will look at products of all stages from pre-clinical to phase III, and is open to all indications. In terms of medical devices, the firm will consider both 510k and PMA devices. In addition, the firm will also consider products that are already on the market.

The firm is open to both public and private companies, and expects them to have an experienced management team with a strong exit strategy. The firm requires a board seat in all portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Arm of Spanish Investment Holding Company Looks to Invest in Therapeutics Companies Across All Disease Areas

11 Feb

A venture capital arm of a large Spanish investment holding company is actively seeking early-stage investment opportunities. A 100 million euros allocation of the fund is dedicated to life sciences investments, while the rest of the fund will focus on investing in manufacturing and digital technology. The typical size of investment can range from 1 to 5 million euros, but the firm has the capacity to invest more in following investments in portfolio companies. The firm can participate at any stage but with preference for investments in Series A and B rounds, and has invested in more than 30 companies. The firm is willing to both lead and co-invest in companies located in Spain and Portugal, and the firm will only participate as a co-investor in European and North American companies. The firm looks to tailor its services to help and collaborate with portfolio companies to reach key value-added milestones.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics companies. The firm is opportunistic in terms of therapeutic areas. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase I.

The firm will invest in privately held companies only. The firm seeks companies with a full-time management team with expertise, successful track records would be a plus but is not required. The firm takes a board seat in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →